In a mouse model of non-alcoholic fatty liver disease, EPO administration in high-fat diet-induced obese mice reduced body weight, improved glucose tolerance and insulin sensitivity, and reduced lipid accumulation in liver and white adipose tissue (WAT) [64]. The gene discussed is EPO; the disease is metabolic dysfunction-associated steatotic liver disease.